Eli Lilly increases investment in "weight loss drug": announces $5.3 billion investment to expand production capacity

Wallstreetcn
2024.05.24 17:23
portai
I'm PortAI, I can summarize articles.

This is the largest investment in the company's nearly 150-year history

According to media reports on Friday, Eli Lilly and Company has made a major decision to invest $5.3 billion to increase the production capacity of tirzepatide, a key ingredient in its weight loss and diabetes injection drugs.

This investment not only adds to existing plans but is also the largest investment in the company's nearly 150-year history.

This will expand its production facilities in Indiana, which produce the active ingredients of the weight loss drug Zepbound and the diabetes blockbuster drug Mounjaro, tirzepatide.

Stay tuned for more updates

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.